Secretome Therapeutics, a pioneering company in the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the ...

Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia ...

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...

Detailed price information for Xortx Therapeutics Inc (XRTX-X) from The Globe and Mail including charting and trades.

Charles Schwab Investment Management Inc. lifted its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free ...

Type B Meeting Discussion to Accelerate XRx-026 for Gout to NDA CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Fra ...

Protagonist Therapeutics is a discovery through late ... is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be ...

Silence Therapeutics (SLN) has been upgraded to a ... in patients with polycythemia vera (PV) were presented at the American Society of Hematology (ASH) Annual Meeting being held in San Diego ...

After hours: March 18 at 4:15:25 PM EDT Loading Chart for VERA ...